No association of single nucleotide polymorphisms involved in GHRL and GHSR with cancer risk: A meta-analysis

Zhu, Shengjie; Shao, Bin; Hao, Yaoyao; Li, Zongxian; Liu, Houqiang; Li, Hong; Wang, Ming; Wang, Kai

doi:10.3233/cbm-140441

Cited by 6 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This analysis found no clear, net effect of ghrelin gene polymorphisms on cancer risk ( Table 1 ), which is consistent with the conclusions of previous meta-analyses that evaluated the same genetic study data across ghrelin and ghrelin-receptor SNPs in patients with varied cancer types ( Pabalan et al 2014 , Zhu et al 2015 ). Follow-up analyses of results showing either positive ( Dossus et al 2008 , Motawi et al 2013 ) or inverse ( Skibola et al 2005 , Wagner et al 2006 , Laurila et al 2014 ) associations of ghrelin gene SNPs with cancer risk warrant further investigation ( Table 1 ).…”

Section: Discussionsupporting

confidence: 88%

Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review

Sever¹,

White²,

García³

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Ghrelin is a hormone with multiple physiologic functions, including promotion of growth hormone release, stimulation of appetite and regulation of energy homeostasis. Treatment with ghrelin/ghrelin-receptor agonists is a prospective therapy for disease-related cachexia and malnutrition. In vitro studies have shown high expression of ghrelin in cancer tissue, although its role including its impact in cancer risk and progression has not been established. We performed a systematic literature review to identify peer-reviewed human or animal in vivo original research studies of ghrelin, ghrelin-receptor agonists, or ghrelin genetic variants and the risk, presence, or growth of cancer using structured searches in PubMed database as well as secondary searches of article reference lists, additional reviews and meta-analyses. Overall, 45 (73.8%) of the 61 studies reviewed, including all 11 involving exogenous ghrelin/ghrelin-receptor agonist treatment, reported either a null (no statistically significant difference) or inverse association of ghrelin/ghrelin-receptor agonists or ghrelin genetic variants with cancer risk, presence or growth; 10 (16.7%) studies reported positive associations; and 6 (10.0%) reported both negative or null and positive associations. Differences in serum ghrelin levels in cancer cases vs controls (typically lower) were reported for some but not all cancers. The majority of in vivo studies showed a null or inverse association of ghrelin with risk and progression of most cancers, suggesting that ghrelin/ghrelin-receptor agonist treatment may have a favorable safety profile to use for cancer cachexia. Additional large-scale prospective clinical trials as well as basic bioscientific research are warranted to further evaluate the safety and benefits of ghrelin treatment in patients with cancer.

show abstract

Section: Discussionsupporting

confidence: 88%

Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review

Sever¹,

White²,

García³

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…For the Basal subtype, we identified a total of 14 genes from the first and second analysis, where 6 genes have been reported to be associated with cancers. Genes MIR124-2 [29], PBX1 [30], SKI [31], GHSR [32] and RBPMS [33] were reported to be associated with breast cancer, and a gene CYP19A1 [34] was reported to be be associated with endometrial cancer. For the Her2 subtype, 34 genes were selected by three methods from both analysis.…”

Section: Resultsmentioning

confidence: 99%

Incorporating genetic networks into case-control association studies with high-dimensional DNA methylation data

Kim

Sun

2019

BMC Bioinformatics

View full text Add to dashboard Cite

BackgroundIn human genetic association studies with high-dimensional gene expression data, it has been well known that statistical selection methods utilizing prior biological network knowledge such as genetic pathways and signaling pathways can outperform other methods that ignore genetic network structures in terms of true positive selection. In recent epigenetic research on case-control association studies, relatively many statistical methods have been proposed to identify cancer-related CpG sites and their corresponding genes from high-dimensional DNA methylation array data. However, most of existing methods are not designed to utilize genetic network information although methylation levels between linked genes in the genetic networks tend to be highly correlated with each other.ResultsWe propose new approach that combines data dimension reduction techniques with network-based regularization to identify outcome-related genes for analysis of high-dimensional DNA methylation data. In simulation studies, we demonstrated that the proposed approach overwhelms other statistical methods that do not utilize genetic network information in terms of true positive selection. We also applied it to the 450K DNA methylation array data of the four breast invasive carcinoma cancer subtypes from The Cancer Genome Atlas (TCGA) project.ConclusionsThe proposed variable selection approach can utilize prior biological network information for analysis of high-dimensional DNA methylation array data. It first captures gene level signals from multiple CpG sites using data a dimension reduction technique and then performs network-based regularization based on biological network graph information. It can select potentially cancer-related genes and genetic pathways that were missed by the existing methods.Electronic supplementary materialThe online version of this article (10.1186/s12859-019-3040-x) contains supplementary material, which is available to authorized users.

show abstract

“…However, researchers should increase the sample size and conduct prospective studies to confirm this relationship. 75…”

Section: Ghrelin Gene (Ghrl)mentioning

confidence: 99%

Multiple roles of ghrelin in breast cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer is one of the most threatening malignant tumors in women worldwide; hence, investigators are continually performing novel research in this field. However, an accurate prediction of its prognosis and postoperative recovery remains difficult. The severity of breast cancer is patient-specific and affected by several health factors; thus, unknown mechanisms may affect its progression. This article analyzes existing literature on breast cancer, ranging from the discovery of ghrelin to its present use, and aims to provide a reference for future research into breast cancer mechanisms and treatment-plan improvement. Various parts of ghrelin have been associated with breast cancer by direct or indirect evidence. The ghrelin system may encompass the direction of expanding breast cancer treatment methods and prognostic indicators. Therefore, we compiled almost all studies on the relationship between the ghrelin system and breast cancer, including unacylated ghrelin, its GHRL gene, ghrelin O-acyltransferase, the receptor growth hormone secretagogue receptor, and several splice variants of ghrelin to lay the foundation for future research.

show abstract

No association of single nucleotide polymorphisms involved in GHRL and GHSR with cancer risk: A meta-analysis

Abstract: Our results suggest that the SNP with GHRL and GHSR might be weaker association with cancer risk, especially with breast cancer risk.

Cited by 6 publications

References 25 publications

Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review

Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review

Incorporating genetic networks into case-control association studies with high-dimensional DNA methylation data

Multiple roles of ghrelin in breast cancer

Contact Info

Product

Resources

About